{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:40Z","timestamp":1790487100187,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":594,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005976","name":"Harry J. Lloyd Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C107\/A10433"],"award-info":[{"award-number":["C107\/A10433"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C309\/A2187"],"award-info":[{"award-number":["C309\/A2187"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ccr.2011.11.004","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T14:21:16Z","timestamp":1323699676000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Leisl\u00a0M.","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareena","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher\u00a0A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rebocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Heidorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew\u00a0S.","family":"Zabriskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Niculescu-Duvaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian\u00a0J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccr.2011.11.004_bib1","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","article-title":"Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells","volume":"109","author":"Bartholomeusz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.11.004_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2011.11.004_bib3","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1073\/pnas.141224398","article-title":"Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism","volume":"98","author":"Chen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2011.11.004_bib4","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.11.004_bib5","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.11.004_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.11.004_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nm0311-286","article-title":"Targeting RAF: trials and tribulations","volume":"17","author":"Downward","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib10","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2011.11.004_bib11","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1073\/pnas.91.13.5982","article-title":"A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function","volume":"91","author":"Fabian","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2011.11.004_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N.\u00a0Engl. J.\u00a0Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0092-8674(95)90277-5","article-title":"Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene","volume":"82","author":"Goga","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.11.004_bib14","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/MCB.16.8.4107","article-title":"Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia","volume":"16","author":"Golub","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2011.11.004_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccr.2011.11.004_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.11.004_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.11.004_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cncr.24928","article-title":"Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ccr.2011.11.004_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2011.11.004_bib20","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-08-2978","article-title":"Sorafenib induces apoptosis specifically in cells expressing BCR\/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway","volume":"69","author":"Kurosu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2011.11.004_bib21","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/j.1460-2075.1995.tb07316.x","article-title":"Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation","volume":"14","author":"Marais","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.ccr.2011.11.004_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1126\/science.280.5360.109","article-title":"Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C","volume":"280","author":"Marais","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ccr.2011.11.004_bib23","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2011.11.004_bib24","doi-asserted-by":"crossref","first-page":"33684","DOI":"10.1074\/jbc.274.47.33684","article-title":"RIP2 is a Raf1-activated mitogen-activated protein kinase kinase","volume":"274","author":"Navas","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2011.11.004_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2796.2001.00823.x","article-title":"Chronic myelogenous leukaemia\u2014new therapeutic principles","volume":"250","author":"O'Dwyer","year":"2001","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.11.004_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"O'Hare","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccr.2011.11.004_bib28","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1126\/science.1103233","article-title":"Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1","volume":"306","author":"O'Neill","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ccr.2011.11.004_bib29","first-page":"447","article-title":"Establishment of a Ph1-positive human cell line (BV173)","volume":"70","author":"Pegoraro","year":"1983","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ccr.2011.11.004_bib30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1083\/jcb.200504137","article-title":"Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling","volume":"171","author":"Piazzolla","year":"2005","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ccr.2011.11.004_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.11.004_bib32","first-page":"122","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Contr."},{"key":"10.1016\/j.ccr.2011.11.004_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","article-title":"The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation","volume":"72","author":"Rahmani","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ccr.2011.11.004_bib34","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib35","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccr.2011.11.004_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","article-title":"BCR-ABL-independent and RAS \/ MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4","volume":"84","author":"Suzuki","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ccr.2011.11.004_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bmcl.2005.09.072","article-title":"The identification of potent and selective imidazole-based inhibitors of B-Raf kinase","volume":"16","author":"Takle","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ccr.2011.11.004_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.11.004_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccr.2011.11.004_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ccr.2011.11.004_bib41","doi-asserted-by":"crossref","first-page":"35ra41","DOI":"10.1126\/scitranslmed.3000758","article-title":"Gatekeeper mutations mediate resistance to BRAF-targeted therapies","volume":"2","author":"Whittaker","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccr.2011.11.004_bib42","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for\u00a0the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccr.2011.11.004_bib43","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610811004107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610811004107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:55:53Z","timestamp":1761522953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610811004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1535610811004107"],"URL":"https:\/\/doi.org\/10.1016\/j.ccr.2011.11.004","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccr.2011.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}